Ana Santos Rutschman

• Professor of Law, Villanova University

Ana Santos Rutschman, professor of law, teaches and researches topics related to health law, intellectual property, innovation in the life sciences and law and technology. She is a nationally and internationally recognized expert on vaccine law and policy, the regulation of emerging health technologies and access to medicines. At Villanova, Rutschman is the founder and director of the Health Innovation Lab, an interdisciplinary platform that brings together academic researchers, students, policymakers, practitioners, industry and the Philadelphia and Northeast Corridor communities.

Rutschman's work has been recognized by numerous institutions, including the American Society of Law Medicine & Ethics, which named her a Health Law Scholar in 2018 and Bio Intellectual Property Scholar in 2017. In 2018, she was also named a Wiet Life Sciences Law Scholar by the Beazley Institute for Health Law and Policy at Loyola University Chicago. In 2022, the Boston Congress of Public Health selected her as one of the inaugural recipients of a 40 Under 40 Public Health Catalyst Award for her work on vaccine law and policy.

Rutschman's book, Vaccines as Technology: Innovation, Barriers and the Public Health, was published in 2022 by Cambridge University Press. Her legal scholarship has appeared or is forthcoming in UCLA Law Review, Emory Law Journal, Indiana Law Journal, UC Davis Law Review, Arizona Law Review, Yale Law Journal Forum, Harvard Public Health Review and Vanderbilt Journal of Transnational Law, among several others. Her peer-reviewed work has appeared in Nature Biotechnology, Vaccine, Emerging Infectious Diseases and American Journal of Infection Control, among others.

• 2022–present Professor, Villanova University
• 2018–2022 Assistant Professor, Saint Louis University School of Law
• 2016–2018 Faculty Fellow in Health Law and Intellectual Property, DePaul University College of Law

• 2016 Duke Law School, SJD
• 2008 Duke Law School, LLM in Intellectual Property

• 2026 The American Asthma Patient, UC Davis Law Review
• 2025 From Myriad to Moderna: The Modern (Bio)Pharmaceutical Company, Texas A&M Journal Property Law
• 2024 The Pressing Need for FDA Regulation of Tattoo Ink (with Lisa Verity and Michael Sinha), Journal of Law the Biosciences
• 2023 Introductory Note to the WTO Ministerial Decision on the TRIPS Agreement, International Legal Materials
• 2023 Increasing Equity in the Transnational Allocation of Vaccines Against Emerging Pathogens: A Multimodal Approach, Journal of Law, Medicine & Ethics
• 2023 Technology Specificity and Equitable Access to Pharmaceuticals, Northwestern Journal of Technology and Intellectual Property
• 2023 Vaccine Contracts in the Context of Pandemics and Epidemics, N.Y.U Journal of International Law & Politics
• 2022 Vaccines as Technology, Cambridge University Press
• 2022 Viral Sovereignty, Vaccine Diplomacy, and Vaccine Nationalism: The Institutions of Global Vaccine Access (with Sam Halabi), Emory International Law Review
• 2022 Public Health Law and Policy in the Wake of NFIB v. OSHA: Probing Emerging Divides in the Supreme Court's View of Public Health (with Ruqaiijah Yearby), N.Y.U. Journal of Legislation and Public Policy Forum
• 2022 Social Media Self-Regulation and the Rise of Vaccine Misinformation, University of Pennsylvania Journal of Law & Innovation
• 2022 Contractual Solutions to Overcome Drug Scarcity During Pandemics and Epidemics (with Sapna Kumar), Nature Biotechnology
• 2022 Vaccine Hesitancy Across Time: Legal and Policy Interventions from the Dawn of the Anti-Vaccination Movement to the Era of Social Media, North Carolina Journal of Law & Technology
• 2021 Intellectual Property as a Determinant of Health, Vanderbilt Journal of Transnational Law
• 2021 Property and Intellectual Property in Vaccine Markets, Texas A&M Property Law Journal
• 2021 Is There a Cure for Vaccine Nationalism?, Current History
• 2021 The COVID-19 Vaccine Race: Intellectual Property, Collaboration(s), Nationalism and Misinformation, Washington University Journal of Law and Policy
• 2021 The Case Against Monetary Behavioral Incentives in the Context of COVID-19 Vaccination (with Timothy Wiemken), Harvard Public Health Review
• 2021 Development of Vaccines for Influenza Disease: Opportunity Costs of the COVID-19 Pandemic (with Timothy Wiemken), Vaccine
• 2021 Vaccine Clinical Trials and Data Infrastructure, Utah Law Review
• 2021 Social Media Self-Regulation and the Rise of Vaccine Misinformation, University of Pennsylvannia Journal of Law and Innovation
• 2020 Regulatory Malfunctions in the Drug Patent Ecosystem, Emory Law Journal
• 2020 The Intellectual Property of Vaccines: Takeaways from Recent Infectious Disease Outbreaks, Michigan Law Review Online
• 2020 A Machine Learning Primer for Infection Prevention and Control (with Timothy Wiemken), American Journal of Infection Control
• 2020 The Reemergence of Vaccine Nationalism, Georgetown Journal of International Affairs Online
• 2019 On the Judicialization of Health, Washington University Global Studies Law Review
• 2019 The Vaccine Race in the 21st Century, Arizona Law Review
• 2018 IP Preparedness for Outbreak Diseases, UCLA Law Review
• 2018 Vaccine Licensure in the Public Interest: Lessons from the Development of the US Army Zika Vaccine, Yale Law Journal Forum
• 2017 The Priority Review Voucher Program at the FDA: From Neglected Tropical Diseases to the 21st Century Cures Act, Annals of Health Law

2017 Bio IP Scholar (American Society of Law, Medicine & Ethics); 2018 Health Law Scholar (American Society of Law, Medicine & Ethics); 2019 Manzo Scholar in Patent Law; 2019 Fellow (CIPPM/Jean Monnet Centre of Excellence for European Intellectual Property and Information Rights); 2022: 40 Under 40 Public Health Catalyst Award, Boston Congress on Public Health

MENAFN12022026000199003603ID1110734305